| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000028762 |
| Receipt No. | R000032448 |
| Official scientific title of the study | The effect on blood pressure of a rice bran peptide containing foods. - Randomized placebo controlled study- |
| Date of disclosure of the study information | 2017/09/14 |
| Last modified on | 2018/09/04 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | The effect on blood pressure of a rice bran peptide containing foods.
- Randomized placebo controlled study- |
|
| Title of the study (Brief title) | The effect on blood pressure of a rice bran peptide containing foods.- Randomized placebo controlled study- | |
| Region |
|
|
| Condition | ||
| Condition | Persons with high-normal blood pressure or mild hype | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To investigate the improvement of blood pressure of repeated ingestion for 12 weeks of a rice bran peptide containing foods. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | <Efficacy>
systolic blood pressure,diastolic blood pressure |
| Key secondary outcomes | <Safety>
Side effect incidence, Adverse event incidence, clinical examination items, and physiological examination items |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Cluster |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Rice bran peptide non-formulated food, 12 weeks | |
| Interventions/Control_2 | Rice bran peptide-containing food, 12 weeks | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1.Males and females equal to or more than 45 years and less than 65 years of age
2.Subjects who contain 130 mmHg <= systolic blood pressure <= 159 mmHg or 85 mmHg <= diastolic blood pressure <= 99 mmHg 3.Subjects equal to less than 30 kg/m^2 of BMI 4.Possible study volunteer to visit 5.Subjects who recognize the object and contents of the study and submit the written informed consent |
|||
| Key exclusion criteria | 1.Pregnant women or breast-feeding women.
2.Individual donated 400 ml of blood within 12weeks or component blood donation 200 ml of blood within 4weeks prior to the study. 3.Individual have already participated other clinical trial or within 4 weeks of examination end. 4.Subjects who have marked impairment of heart,liver, kidney, thyroid, and other diseases. 5.Subjects who have a history of cardiovascular disease 6.Subjects who develop diabetes(Recommended by Japan Diabetes Society). 7.Subjects who have food allergy against brown rice, rice bran, and rice 8.Individual experienced unpleasant feeling by drawing blood in the past. 9.Heavy drinkers 10.Heavy Smokers(More than daily an average of 21 of them) 11.Subjects whose eating habits are extremely irregular 12.Subjects who take medications that may affect this exam 13.Subjects who regularly using foods such as specified health foods and functional display foods that may affect this inspection 14.Secondary hypertension 15.Subjects who have a history of large surgery(gastrectomy, gastrointestinal suture, intestinal resection) on the gastrointestinal except who resect the cecum. 16.Individual who was judged ineligibles by clinician in this trial. |
|||
| Target sample size | 80 | |||
| Research contact person | |
| Name of lead principal investigator | Motonobu Matsumoto |
| Organization | Sunstar Inc. |
| Division name | General Manager R&D |
| Address | 3-1, Asahimachi, Takatsuki, Osaka,Japan |
| TEL | 072-682-5570 |
| motonobu.matsumoto@jp.sunstar.com | |
| Public contact | |
| Name of contact person | Yoshitaka Hatakeyama |
| Organization | New Drug Research Center, Inc. |
| Division name | Clinical Research Dept. |
| Address | 452-1Toiso,Eniwa-shi,Hokkaido, Japan |
| TEL | 0123-34-0412 |
| Homepage URL | |
| y-hatakeyama@ndrcenter.co.jp | |
| Sponsor | |
| Institute | Sunstar Inc. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Sunstar Inc. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000032448 |